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 Melanoma is a malignant neoplasm with a very high rate of growth in the number of cases. In Poland, in the years 1980–2010, 
the number of cases of melanoma increased threefold. Although the incidence rates of melanoma are rising, the mortality 
rate due to melanoma is falling. In recent years, the treatment of patients with melanoma has changed to a great extent. 
Thanks to the development of molecular research, the presence of specific mutations in melanoma cells was discovered. 
The progress in understanding the molecular mechanisms occurring in this neoplastic cells and the interaction between 
the immune system cells and melanoma cells contributed to the development of new classes of drugs: immunotherapy 
and targeted therapy.
 With the use of checkpoint inhibitors, long-term remission of the disease can be achieved, which has been confirmed 
in many clinical trials that have shown improvements in overall survival (OS) and progression free survival (PSF). How-
ever, the predominant problem is the low response rate to checkpoint inhibitors and the time between the initiation of 
therapy and the response to treatment. This is not the case with targeted therapies, where the response rate is high and 
the response time is very short. Therefore, a promising treatment strategy can be a combination of these two classes of 
drugs, so that one can try to achieve a quick and long-term response to the treatment. The paper discusses the current 
treatment options for melanoma patients in the spreading phase of the disease and analyzes the benefits of combined 
and sequential treatment. 
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Introduction
Melanoma is a malignant neoplasm with a very high rate of 
growth in the number of cases. In Poland, in the years 1980–
2010, the number of cases of melanoma increased threefold 
[1, 2]. Although the incidence rates of melanoma are rising, the 
mortality rate due to melanoma is falling. Low grade melanoma 
has a very good prognosis and is usually completely curable 
with surgical methods, while 5-years survival rate reaches as 
much as 99%. However, melanomas with metastases to regio-
nal lymph nodes or distant metastases are characterized by 
much worse prognosis: 5-year survival rates are 63% and 20% 
respectively [3]. Despite significant progress, the prognosis 
of patients with melanoma in the spreading phase of the 
disease is still unsatisfactory and new treatment strategies are 
constantly being sought. 
In recent years, the treatment of patients with melanoma 
has changed to a great extent. Thanks to the development 
of molecular research, the presence of specific mutations in 
melanoma cells was discovered. It is estimated that melanoma 
cells show BRAF V600 mutation in about 50% of patients with 
disseminated melanoma [4]. The progress in understanding 
the molecular mechanisms occurring in melanoma cells and 
the interaction between the immune system cells and mela-
noma cells contributed to the development of new classes of 
drugs: immunotherapy and targeted therapy. Immunotherapy 
is based on immune checkpoint inhibitors (ICIs), which inc-
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lude anti-cytotoxic T-lymphocyte antigen 4 antibodies (anti-
-CTLA-4) and anti-programmed death receptor-1/ligand-1 
(anti-PD-1/anti-PD-L1) antibodies. The first registered ICI drug 
was ipilimumab (anti-CTLA-4), followed by nivolumab and 
pembrolizumab (anti-PD-1). Another group of drugs is targeted 
therapy, which includes BRAF inhibitors (BRAFi; vemurafenib, 
dabrafenib and encorafenib) and MEK inhibitors (MEKi; cobi-
metinib, trametinib, binimetinib). It is also worth mentioning 
the introduction of oncolytic talimogene laherparepvec virus 
(T-VEC) to the treatment of patients with melanoma.
With the use of checkpoint inhibitors, long-term remission 
of the disease can be achieved, which has been confirmed in 
many clinical trials that have shown improvements in overall 
survival (OS) and progression free survival (PSF). However, the 
predominant problem is the low response rate to checkpoint 
inhibitors and the time between the initiation of therapy and 
the response to treatment. This is not the case with targeted 
therapies, where the response rate is high and the response 
time is very short. Therefore, a promising treatment strategy 
can be a combination of these two classes of drugs, so that one 
can try to achieve a quick and long-term response to the tre-
atment. The paper discusses the current treatment options for 
melanoma patients in the spreading phase of the disease and 
analyzes the benefits of combined and sequential treatment. 
Immunotherapy
Anti-CTLA-4 or anti-PD-1 monotherapy
Ipilimumab
Ipilimumab is a recombinant human monoclonal antibody, 
IgG1 subclass, with a half-life of 12–14 days, binding to the 
CTLA-4 (CD152) molecule [14]. By blocking CTLA-4, the an-
ti-neoplastic immune response is activated. Three phase II 
studies – CA184-022, CA184-008 and CA184-007 [5–7] – using 
ipilimumab in monotherapy in patients with advanced mela-
noma showed a median survival rate of 8.6–11.0 months and 
a percentage of 1-year survival rate of 39–48%. Subsequent 
analyses showed a 2-year survival rate of 30% [8] and a 3-year 
survival rate of 25% at the dose of 10 mg/kg of body weight. 
[9]. However, there is no data available to indicate that this drug 
leads to permanent cures in melanoma patients. In 2010, the 
results of the phase III study (MDX010-20) using ipilimumab in 
patients with advanced melanoma were presented [10]. The 
median survival time of patients treated with ipilimumab was 
10.0 months, of patients treated with ipilimumab and gp100 
– 10.1 months and in both cases it was significantly higher 
than in the control group (median survival time: 6.4 months). 
In 2011, in a study evaluating the efficacy of ipilimumab at 
the dose of 10 mg/kg of body weight (in combination with 
dacarbazine) in the first-line therapy, long-term responses were 
demonstrated in some patients and an improvement in total 
survival rate (the percentage of 2-year OS was 28.5%) [11, 12]. 
The analysis of 12 clinical trials confirmed the potential long-
-term effect of ipilimumab on the survival rate, and the 10-year 
survival curve reached a plateau at about 20% [13]. However, 
ipilimumab is not currently used in monotherapy as first-line 
option treatment. 
Nivolumab and pembrolizumab
Nivolumab has a structure of a human monoclonal IgG4 anti-
body with a half-life of approximately 26 days and is specific to 
the PD-1 receptor. The mechanism of action of both nivolumab 
and pembrolizumab is to bind the drug to the PD-1 receptor 
and block the interaction with PD-L1 and PD-L2 ligands, which 
in turn activates T-lymphocytes for an immune response aga-
inst neoplastic cells [14]. Two large phase III studies, CheckMa-
te-066 [15] and CheckMate-037 [16], confirmed the efficacy 
of nivolumab in the treatment of melanoma patients. In the 
CheckMate-066 study, nivolumab was used as the first-line 
treatment in patients without BRAF mutations. The comparator 
in the study was dacarbazine. The percentage of 2-year-old OS 
for nivolumab was 57.7% and PSF 39.2% [17], the percentage 
of 3-year-old OS was 51.2% and PFS 21.6%. The number of ob-
jective responses to nivolumab was 40% and to dacarbazine it 
was 13.9% [18]. The OS median for nivolumab was 37.5 months 
and 11.2 months for dacarbazine. In turn the median PFS was 
5.1 and 2.2 months respectively [15, 18]. In the CheckMate-037 
study, nivolumab was used as a follow-up treatment in patients 
after ipilimumab and BRAFi if a mutation was found in the BRAF 
gene. Dacarbazine or paclitaxel with carboplatin were used as 
comparators. The median OS in this study was 16 months for 
nivolumab and 14 months for chemotherapy and the median 
PFS: 3.1 and 3.7 months, respectively; objective responses were 
obtained in 27% and 10% patients, respectively [19].
Pembrolizumab is a humanized monoclonal IgG4 antibody 
with a half-life of about 27 days [20]. Its efficacy was confirmed 
in phase III KEYNOTE-006 study, with the participation of pa-
tients with advanced melanoma, who had not been previously 
taken part in systemic treatment. Patients were assigned to 
3 groups of patients receiving pembrolizumab every 2 or 3 
weeks or ipilimumab [21]. The median OS was 32.7 months 
in groups treated with pembrolizumab and 15.9 months in 
groups treated with ipilimumab. The median PFS was 8.4 and 
3.4 months respectively [22, 23]. Objective responses were 
obtained in the group receiving pembrolizumab every 2 or 3 
weeks in 33.7% and 32.9% of patients respectively, and in the 
group treated with ipilimumab in 11.9% [21].
Combination therapy using anti-CTLA-4 with 
anti-PD-1
The first attempts to combine CTLA-4 and PD-1 inhibitors 
were made in phase I, where the combination of nivolumab at 
a dose of 1 mg/kg of body weight with ipilimumab at a dose of 
3 mg/kg of body weight was tested [24]. The basic study that 
evaluated the efficacy of combination therapy: nivolumab with 
ipilimumab was the phase III study CheckMate-067 [25]. The 
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median OS was not obtained in the group receiving nivolumab 
with ipilimumab, in the group with nivolumab it was 36.9 
months, and in the group with ipilimumab 19.9 months. The 
median PFS reached 11.5 months, 6.9 months and 2.9 months 
respectively, with objective responses of 57.6%, 43.7% and 
19% respectively. It should be noted that the combination of 
nivolumab with ipilimumab gave better results in patients with 
low expression of PD-L1 in melanoma tissue (<5%). In case of 
high expression of PD-L1 in melanoma tissue, the treatment 
results for monotherapy with nivolumab and combined the-
rapy with PFS and OS were similar [25]. Adverse events related 
to treatment in grade 3 and 4 have been reported:
• in the group receiving nivolumab with ipilimumab – in 
185 (59%) out of 313 patients, 
• in the group receiving nivolumab – in 70 (22%) out of 
313 patients,
• in the group receiving ipilimumab – in 86 (28%) out of 
311 patients [26, 27]. 
Another study that evaluated the association of anti-CTLA-4 
with anti-PD-1 was the III/IV phase of CheckMate-511 study [28]. 
It compared 2 different doses of both drugs, i.e. nivolumab at 
a dose of 1 mg/kg of body weight with ipilimumab at a dose of 
3 mg/kg of body weight (NIVO1+IPI3) and nivolumab at a dose 
of 3 mg/kg of body weight with ipilimumabat a dose of 1 mg/kg 
of body weight. (NIVO3+IPI1). Objective response to treatment 
was obtained in 45.6% of cases in the NIVO3+IPI1 group and 
50.6% in the NIVO1+IPI3 group, and the percentage of complete 
remissions – (CR) was 15.0% and 13.5% respectively. The median 
OS was not obtained in any of the groups and the median PFS 
was 9.9 months in the NIVO3+IPI1 group and 8.9 months in the 
NIVO1+IPI3 group. Annual PFS was 47.2% and 46.4% respectively 
and annual OS was 79.7% and 81% respectively. 
The association of pembrolizumab at a dose of 2 mg/kg 
of body weight with ipilimumab at a low dose of 1 mg/kg of 
body weight at the phase Ib of KEYNOTE-029 study was also 
evaluated. The number of objective responses to treatment 
was 61%, including 15% of CR. In 27% of treated patients ad-
verse effects were reported in grades 3 and 4 [29, 30].
Targeted therapy
Monotherapy with BRAF orMEK inhibitors
Vemurafenib
Vemurafenib is a low molecular weight BRAF serine threonine 
kinase inhibitor used in melanoma patients with mutations in 
the BRAF gene [31]. In phase III of the BRIM-3 study, vemurafenib 
and dacarbazine were compared in patients with advanced me-
lanoma, who had not previously undergone systemic treatment, 
with the presence of mutations in the BRAF V600E gene [32]. 
The median OS in the group receiving vemurafenib was 13.6 
months and in the group with dacarbazine – 9.7 months in the 
analysis before cross-over to vemurafenib (in the analysis after 
cross-over the median OS was 10.3 months). The median PFS 
was 6.9 and 1.6 months respectively [32, 33]. The 1-, 2-, 3- and 
4-year survival rate constituted 56% and 46%, 30% and 24%, 
21% and 19%, as well as 17% and 16%, respectively. In the group 
receiving vemurafenib, 48% of responses to treatment were 
reported, and in the group treated with dacarbazine – 5% [32].
Dabrafenib
Dabrafenib is a reversible BRAF V600 kinase inhibitor used in 
melanoma patients with mutations in the BRAF gene. In the 
BREAK-3 study, dabrafenib was compared with dacarbazine 
in patients with advanced melanoma with the present BRAF 
V600E mutation who had not received previous systemic tre-
atment. Because of the planned cross-over to dabrafenib after 
disease progression, the primary endpoint was PFS, which in 
the group with dabrafenib was 5.1 months and in the group 
with dacarbazine – 2.7 months [34]. According to data pre-
sented at the ASCO conference in 2013, the median OS in 
the dabrafenib-treated group was 18.2 months and in the 
dacarbazine-treated group 15.6 months, while the number of 
responses to dabrafenib treatment was 59% [17].
Encorafenib
Encorafenib, like dabrafenib and vemurafenib, it is an inhibitor 
of BRAF V600 kinase. However, it differs from them by 10 times 
longer half-life of dissociation (>30 h). This probably results in 
higher antineoplastic activity and at the same time less activa-
tion of the MAPK pathway in healthy tissues, which is responsible 
for the development of adverse effects [37]. The combination 
of encorafenib with binimetinib compared to encorafenib or 
vemurafenib was evaluated in the COLUMBUS study [43, 44]. 
Trametinib
Trametinib is an oral, low-molecular, selective inhibitor of MEK1 
and MEK2 kinase. Trametinib was evaluated in phase III of the 
METRIC study and compared with chemotherapy (dacarbazine 
or paclitaxel) in patients with advanced melanoma with BRAF 
V600E/K mutation [35]. In this study, the median PFS was 
4.9 months for trametinib and 1.5 months for chemotherapy, 
and 1-, 2-, 5-year total survival for trametinib and chemo-
therapy was 60.9% and 49.6%, 32.0% and 29.4%, 13.3% and 
17.0% respectively. In the vast majority of patients at the early 
stage of treatment, a cross-over (n = 70, 65%) to trametinib 
was used [36].
Binimetinib
Binimetinib, just as trametinib, is an oral, low-molecular, selective 
inhibitor of MEK1 and MEK2 kinase. Its efficacy was assessed in a 
phase III study with NEMO randomization, where it was compared 
with dacarbazine in patients with advanced melanoma with NRAS 
mutation. The median OS in the group receiving binimetinib was 
11 months, and in the group receiving dacarbazine – 10.1 months. 
The median PFS was 2.8 and 1.5 months respectively, and the rate 
of responses was 15% and 7% respectively [38]. 
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Therapy combined with BRAF and MEK inhibitors
Vemurafenib with cobimetinib
The efficacy of the combination of vemurafenib and cobi-
metinib was confirmed by phase III of coBRIM study [39]. It 
showed the advantage of combination of vemurafenib and 
cobimetinib over monotherapy with vemurafenib. The median 
OS and PFS for the combination was 22.3 and 12.3 months for 
the combination and 12.3 and 7.3 months for the vemurafenib 
respectively. Similarly, the number of objective responses for 
vemurafenib with comimetinib was 70% and 50% respectively. 
One of the advantages of using the combination in compari-
son with monotherapy with BRAF inhibitor was significantly 
lower number of skin complications.
Dabrafenib with trametinib 
The combination of dabrafenib and trametinib was evaluated 
in two studies of the third phase of COMBI-d [40] and COMBI-v 
[41]. In the first one, dabrafenib with trametinib was compared 
to dabrafenib and in the second one to vemurafenib. The me-
dian OS in COMBI-d was 25.1 months for the combination and 
18.7 months for the trametinib, the median PFS was 11 and 8.8 
months respectively, while the number of objective responses 
to treatment ranged from 69% to 53%. In the COMBI-v study, 
the median OS for the combination was 25.6 months and for 
vemurafenib 18 months, while the median PFS was 11.4 and 
7.3 months, respectively, and the number of responses to 
treatment was 64% and 51%. The updated 5-year follow-ups 
in COMBI-d and COMBI-v showed a 4-year PFS of 21% and a 
5-year PFS of 19%. Four-year OS was 37% and five-year OS was 
34%. Total remission was observed in 19% of patients with 
5-year-old OS at 71% [42].
Encorafenib with binimetinib
The efficacy of the combination of encorafenib and binimetinib 
was evaluated in the COLUMBUS study [43, 44]. Encorafenib 
and binimetinib were compared with encorafenib or vemu-
rafenib. The OS median for the combination was 33.6 months 
and 16.9 months for vemurafenib. The median PFS for enco-
rafenib with binimetinib was 14.9 months, for encorafenib 
9.6 months and for vemurafenib 7.3 months. However, the 
number of objective responses to treatment was 64%, 52% 
and 41% respectively. 
Immunotherapy with targeted therapy
Combinations of immunotherapy and targeted therapy are 
currently being tested in many clinical trials. This treatment 
is used in patients with melanoma with the current mutation 
in the BRAF gene. This combination of therapies seems very 
promising. It enables a significant number of responses to be 
obtained in a short time using BRAFi/MEKi and a long-term 
maintenance of these responses during treatment with check-
point inhibitors. Another justification for this management 
strategy is based on different mechanisms of action of indi-
vidual therapies, which, due to their complementary action, 
may improve the effects of treatment [45]. 
The first combinations of targeted therapies with immuno-
therapy for melanoma referred to ipilimumab and vemurafe-
nib. However, the study was discontinued due to significant 
hepatotoxicity of combined therapy [46]. Subsequent studies 
concerned the combination of ipilimumab or nivolumab or 
pembrolizumab with dabrafenib and trametinib [47]. The first 
results of treatment with pembrolizumab, dabrafenib and 
trametinib are promising, with PFS of 16 months and 59.8% 
response rates with a median response time of 18.7 months 
and acceptable treatment toxicity [47]. The study evaluating 
the toxicity of the combination of atezolizumab, vemurafenib 
and cobimetinib resulted in 71.8% objective responses and 
39.3% with a median response duration of 17.4 months [48]. 
Currently, patients with advanced melanoma are undergoing 
a number of clinical trials to combine targeted therapy with 
immunotherapy, but most often these are phase I and phase 
II studies [49]. However, the results of treatment of patients 
with advanced melanoma are still yet to come, as they require 
confirmation in subsequent clinical trials. 
Strategy of management of patients with 
advanced melanoma
At present, the following therapies are registered for the tre-
atment of patients with melanoma in inoperable grade III 
and grade IV:
Combined treatment
a) patients with a present mutation in the BRAF gene: 
• dabrafenib with trametinib
• encorafenib with binimetinib
• vemurafenib with cobimetinib
• nivolumab with ipilimumab 
b) patients with no mutation in the BRAF gene:
• nivolumab with ipilimumab (currently not refundable in 
Poland).
Monotherapy
a) patients with a mutation in the BRAF gene:
• dabrafenib
• trametinib
• vemurafenib
• nivolumab
• pembrolizumab
• iplimumab
b) patients with no mutation in the BRAF gene:
• nivolumab
• pembrolizumab
• iplimumab.
In the light of current studies, the use of targeted therapies 
as monotherapy may be justified only in case of significant 
complications during BRAFi-MEKi combination therapy [39–
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44]. However, if complications occur during combined therapy, 
the combination of BRAFi and MEKi with a different toxicity 
profile should be considered first. In the case of checkpoint 
inhibitors, the use of immunotherapy as a monotherapy is pre-
ferred in most patients due to its low toxicity. The combination 
of nivolumab and ipilimumab should be recommended espe-
cially in patients with asymptomatic CNS metastases [50–52]. 
However, the sequence of therapies, especially in patients with 
the present mutation in the BRAF gene, remains a problem. 
A very practical solution was proposed in the work by 
Schvartsman et al. [50]. He distinguished two prognostic gro-
ups among patients with melanoma in inoperable grade III 
and in grade IV: low and high risk (table I). Then, depending 
on the risk group and the presence or absence of metastases 
in the CNS, he presented 4 possible scenarios of management 
(fig. 1–4):
• low-risk patients without metastases in CNS;
• low-risk patients with metastases in CNS;
• high-risk patients without metastases in CNS;
• high-risk patients with metastases in CNS.
Such a division can be very useful in everyday medical prac-
tice. It seems that if the patient is in good general condition, the 
tumor mass is small and occurs in 1–2 locations and the LDH level 
is normal or slightly elevated, the best option is to start therapy 
with checkpoint inhibitors. Of course, attention should be paid to 
possible contraindications to immunotherapy and a discussion 
with the patient about other available therapeutic options. 
In situations where the disease is rapidly progressing and a 
mutation is present in the BRAF gene, BRAFi and MEKi are the 
therapies of choice (in some cases checkpoint inhibitors may 
also be considered). One can also optionally start treatment 
with BRAFi and MEKi (for a short period of time) to stop the 
neoplastic process and then move on to immunotherapy. 
However, new therapeutic options and drug combinations 
are being sought to achieve long-term survival in this group 
of patients.
Low-risk patient without metastases in CNS
• anti-PD-1 (nivolumab or pembrolizumab)
or
• nivolumab with ipilimumab*
*preferred in patients with BRAF mutation, high level of LDH or negative 
PD-L1, however. there is no management consensus
Progression
BRAF+ BRAF–
BRAFi + MEKi
• encorafenib + binimetinib or
• dabrafenib + trametinib or
• vemurafenib + cobimetinib
No clear guidelines:
• clinical study
• ipilimumab (if anti-PD-1 monotherapy used earlier)
• chemotherapy
• radiotherapy + anti-PD-1
• HD IL-2
• T-VEC (if lesions in skin or subcutaneous tissue are present)
• symptomatic treatment
Low-risk group
• tumor mass size (total volume) <10 cm
• number of metastases locations <3 locations
• normal LDH level
• radioterapia + anty PD-1
• performance status 0 or 1
Figure 1. Management algorithm 1. Low-risk patient without metastases in CNS
Table I. Prognostic groups of patients according to Schvartsman et al. [50]
Factor/group Low-risk group High-risk group
Tumor mass size (total volume) <10 cm ≥10 cm
Number of locations where metastases were found <3 locations ≥3 locations
LDH concentration value Normal ≥2 × upper limit of normal
Performance status 0 or 1 ≥2
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Low-risk patient with metastases in CNS
• anti-PD-1 (nivolumab or pembrolizumab)
or
• stereotactic radiotherapy with anti-PD-1 (surgical excision should be considered in the case of large single lesions 
that cannot be treated with stereotactic radiotherapy or if treatment with steroids is necessary) or
• anti-PD-1  (nivolumab or pembrolizumab)
Progression
(if progression only to CNS, stereotactic radiotherapy and continued immuno-
therapy should be considered)
BRAF+ BRAF–
BRAFi + MEKi
• encorafenib + binimetinib or
• dabrafenib + trametinib or
• vemurafenib + cobimetinib
No clear guidelines:
• clinical study
• ipilimumab (if anti-PD-1 monotherapy used earlier)
• chemotherapy
• symptomatic treatment
Low-risk group
• tumor mass size (total volume) <10 cm
• number of metastases locations <3 locations
• normal LDH level
• performance status 0 or 1
High-risk patient without metastases in CNS 
Progression
(patients with BRAF 
mutation)
BRAF+ BRAF–
BRAFi + MEKi
• encorafenib + binimetinib or
• dabrafenib + trametinib or
• vemurafenib + cobimetinib
• nivolumab with ipilimumab (preferred option)
or
• anti-PD-1 (nivolumab or pembrolizumab)
High-risk group
• tumor mass size (total volume) ≥10 cm
• number of metastases locations ≥3 locations
• LDH level: 2 × upper limit of normal
• performance status ≥2
Progression
(patients should be monitored very carefully for the 
progression of the disease and if it occurs, immunothe-
rapy should be started immediately)
Figure 2. Management algorithm 2. Low-risk patient with metastases in CNS
Figure 3. Management algorithm 3. High-risk patient without metastases in CNS
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Summary
The emergence of new therapies has certainly improved the 
survival rates of melanoma patients. However, there is still 
a group of patients in whom the efficacy of the treatment is 
unsatisfactory and further research is needed to answer the 
question: “Why do these patients not respond to the treatment 
applied?”. Other problems have also emerged in relation to 
the toxicity of new drugs and the sequence and duration of 
treatment, which require further research. 
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Progression
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BRAFi + MEKi
• encorafenib + binimetinib or
• dabrafenib + trametinib or
• vemurafenib + cobimetinib
• nivolumab with ipi-
limumab (preferred 
option) 
or
• anti-PD-1 (nivolumab or 
pembrolizumab)
High-risk group
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• LDH level: 2 × upper limit of normal
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